336 related articles for article (PubMed ID: 28278193)
21. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
23. Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.
El Missiry M; Hjorth-Hansen H; Richter J; Olson-Strömberg U; Stenke L; Porkka K; Kreutzman A; Mustjoki S
PLoS One; 2017; 12(1):e0171041. PubMed ID: 28135325
[TBL] [Abstract][Full Text] [Related]
24. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
25. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
26. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
27. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
28. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
Zhang J; Wang Y; Wang J; Hu J; Chen S; Jin J; Liu T; Zhou J; Hu Y; Ma D; Huang X; Ji C; Hou M
Blood Cancer J; 2018 Jun; 8(7):61. PubMed ID: 29915172
[TBL] [Abstract][Full Text] [Related]
29. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
[TBL] [Abstract][Full Text] [Related]
30. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
Moore FR; Rempfer CB; Press RD
Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
[TBL] [Abstract][Full Text] [Related]
31. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
Arora R; Press RD
Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
[TBL] [Abstract][Full Text] [Related]
32. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
Mahon FX; Etienne G
Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
[TBL] [Abstract][Full Text] [Related]
33. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
34. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Sasaki K; Kantarjian H; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce S; Jabbour E; Cortes JE
Cancer; 2018 Mar; 124(6):1160-1168. PubMed ID: 29266206
[TBL] [Abstract][Full Text] [Related]
35. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
36. BCR-ABL1 RT-qPCR for monitoring the molecular response to tyrosine kinase inhibitors in chronic myeloid leukemia.
Press RD; Kamel-Reid S; Ang D
J Mol Diagn; 2013 Sep; 15(5):565-76. PubMed ID: 23810242
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
Lai Y; Qin Y; Huang X; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
[TBL] [Abstract][Full Text] [Related]
38. Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.
Gerrard G; Foong HE; Mudge K; Alikian M; Apperley JF; Foroni L
Leuk Res; 2016 Oct; 49():47-50. PubMed ID: 27552679
[TBL] [Abstract][Full Text] [Related]
39. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
Bernardi S; Malagola M; Zanaglio C; Polverelli N; Dereli Eke E; D'Adda M; Farina M; Bucelli C; Scaffidi L; Toffoletti E; Deambrogi C; Stagno F; Bergamaschi M; Franceschini L; Abruzzese E; Divona MD; Gobbi M; Di Raimondo F; Gaidano G; Tiribelli M; Bonifacio M; Cattaneo C; Iurlo A; Russo D
Cancer Med; 2019 May; 8(5):2041-2055. PubMed ID: 30950237
[TBL] [Abstract][Full Text] [Related]
40. Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.
O'Dwyer ME; Swords R; Nagler A; McMullin MF; le Coutre PD; Langabeer SE; Alvarez-Iglesias A; Fan H; Woodman RC; Giles FJ; Conneally E
Leuk Res; 2014 Mar; 38(3):310-5. PubMed ID: 24333114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
